In recent years, precision medicine has become a medical development trend. DIAN Diagnostics has taken a series of actions over the past two years: in November 2017, DIAN joined hands with Danaher Group in the field of mass spectrometry detection, and in April 2018, established cooperation with Roche and FMI in the field of precision diagnostics of tumors. On July 4, DIAN took another action to cooperate with Agena Bioscience (hereinafter called “Agena”), constantly making new contributions to promote the transformation and application of international advanced diagnosis and treatment technology in China.
Recently DIAN Diagnostics declared its commercial cooperation with Agena. The two parties would make joint efforts to accelerate the promotion of technical platforms of nucleic acid mass spectrometry and the diagnostic schemes of multiple DNA gene detection in Chinese market, and would be devoted to the clinical research and practice of life science and precision medicine, to promote the final implementation of precision medicine plan in China.
At the signing ceremony
As a part of this cooperation, DIAN Diagnostics will be authorized to sell core products of Agena on its designated platforms in China, and will rely on Agena’s global leading technology on nucleic acid mass spectrometry platforms and DIAN’s laboratory network and channel resources all over China to co-build the “nucleic acid mass spectrometry demonstration laboratory of China”, develop and establish customer and expert resources in the field of genetic diseases, pharmacogenomics and infectious diseases, and promote the formation of clinical application guidelines for nucleic acid mass spectrometry diagnosis projects and of the industrial technical application standards, so as to improve the competence of distribution and service network to clinical hospitals and promote the development of diagnostic technology, clinical application and industrialization of genomics.
Message from Mao Xihao, member of the Standing Committee of the CPC, Hangzhou Municipal Committee and secretary of Yuhang District Committee
At the launching ceremony, Mao Xihao, member of the Standing Committee of the CPC, Hangzhou Municipal Committee and secretary of Yuhang District Committee addressed that as the biomedical industry would be given top priority in the next-round development of Yuhang District, the launch of the US-China nucleic acid mass spectrometry project would inject new impetus into domestic R & D and industrialization, and the implementation of this project in Yuhang District would greatly benefit the booming Yuhang Economic and Technological Development Zone and even the development of Hangzhou’s biochemical industry.
Message from Su Zhiliang, member of the party group of Zhejiang Food and Drug Administration and the chief engineer
Su Zhiliang, member of the party group of Zhejiang Food and Drug Administration and the chief engineer, introduced the good situation of review and approval of medical devices in China and Zhejiang Province, and mentioned that DIAN’s cooperation with Agena, which introduced international advanced technology and equipment into China, was a project encouraged by “Made in China 2025”, and was of great significance to narrow the gap between China and the world in advanced level and to improve the clinical detection level. It was hoped that this cooperation would be able to build an international project with first-class quality, management and innovation from the global perspective, and became a demonstration to lead the development of China’s medical device industry.
Message from Chen Haibin, chairman of DIAN Diagnostics
Chen Haibin, chairman of the board of directors, reviewed the development course of DIAN Diagnostics and pointed out that for the purpose of development, DIAN must transform from the era competing with speed, physical strength and width into an era competing with endurance, competence and depth, and the future development must be driven by technical innovation. As the premise of precision medicine, precision diagnostics has two major technical platforms-gene sequencing and biological mass spectrometry, which is why DIAN has been focusing on the development of precision diagnostics in recent years. This cooperation with Agena has complementary advantages, which will combine DIAN’s strengths of brand, channel, capital and service in China to promote the transformation of international advanced DNA gene mass spectrometry technology in China based on the characteristics of China’s market, so as to benefit Chinese patients. Meanwhile, DIAN Diagnostics will maintain its original intention and ingenuity, keep innovative, aspire to become the leader in the field of precision diagnostics in China, and contribute to life science, healthy Hangzhou and healthy China.
Message from Peter Dansky, CEO of Agena Global
Peter Dansky, CEO of Agena Global, first introduced his deep impression on the speed of decision-making and the evolution in China, who also addressed that the mission of Agena was to improve clinical decision-making by providing advanced and economic diagnostic technologies, to enable doctors to achieve precision diagnostics of their patients. DIAN Diagnostics was an ideal partner of Agena since it shared the same strategic vision and values as Agena and had a nationwide business network of clinical detection services and abundant sales channels for clinical diagnostic products. Together, the two parties would open up a new road to improve the medical decision-making of millions of Chinese people and the current medical situation in China!
At the ceremony, Tian Yaping, director of the biochemistry department of Beijing PLA General Hospital, CEO Peter Dansky, chairman Chen Haibin, and Wang Bofei, vice president of Agena Global and regional general manager of Agena China, et al. also discussed with many media reporters on the theme of “in-depth promotion and application of nucleic acid mass spectrometry technology in China's clinical market”, and exchanged ideas about the advantages of such technology, the application prospect in China’s clinical market and the benefit and significance to the society and the public.
Interaction with on-site media
The cooperation between DIAN Diagnostics and Agena on the introduction and implementation of China-US nucleic acid mass spectrometry project in China will make it no longer far away to use the mass spectrometry technology leading in the world, effectively reduce China’s medical expenses, and directly benefit the general public, which will become a new milestone in the history of China-US mass spectrometry.
Agena Bioscience,Inc.
As an innovative high-tech biotechnology company, Agena Bioscience,Inc. (previously Sequenom) supplies products including nucleic acid mass spectrometers and supporting reagents and consumables, and is devoted to developing mass spectrometry gene analysis technology with high sensitivity, high accuracy and low cost, to provide excellent solutions for the research and clinical application of pharmacogenomics, genetic diseases, tumors, non-invasive prenatal screening, quantitative analysis of DNA methylation, etc.
Its core technical platform- MassARRAY clinical application system of nucleic acid mass spectrometry technology, is established on the technical basis of mass spectrometer to realize the analysis of gene site mutations and some CNV copy number variations, which is of high precision, high sensitivity, flexible flux, convenience and promptness, low lost and no need of complex health information analysis. Currently the device system has been applied in 37 countries around the world, and has become an ideal clinical diagnosis platform to largely contribute to clinical precision diagnosis in the fields of prenatal diagnosis, neonatal screening, individualized cancer diagnosis, genetic disease screening, pharmacogenomics, infectious diseases and cardiovascular diseases.
